Colton Groome Financial Advisors LLC Makes New Investment in Danaher Corporation $DHR

Colton Groome Financial Advisors LLC bought a new position in Danaher Corporation (NYSE:DHR) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor bought 2,674 shares of the conglomerate’s stock, valued at approximately $592,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. EP Wealth Advisors LLC bought a new position in shares of Danaher in the 2nd quarter worth about $3,807,000. Puzo Michael J bought a new stake in Danaher during the second quarter worth about $8,624,000. First Nebraska Trust Co purchased a new stake in Danaher in the second quarter worth about $14,106,000. Madison Asset Management LLC bought a new position in shares of Danaher during the second quarter valued at approximately $85,451,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in shares of Danaher during the second quarter valued at approximately $11,800,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of Danaher stock traded down $3.48 on Tuesday, hitting $217.73. 1,774,393 shares of the company’s stock were exchanged, compared to its average volume of 4,452,227. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The company has a 50-day simple moving average of $209.69 and a 200-day simple moving average of $193.88. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The stock has a market capitalization of $153.06 billion, a PE ratio of 38.67, a PEG ratio of 2.67 and a beta of 0.76.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The firm had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same period in the prior year, the business posted $0.77 EPS. Danaher’s revenue was up 5.5% on a year-over-year basis. As a group, equities analysts anticipate that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. Danaher’s dividend payout ratio (DPR) is 28.42%.

Wall Street Analyst Weigh In

DHR has been the topic of a number of recent research reports. UBS Group assumed coverage on Danaher in a research note on Wednesday, September 9th. They issued a “buy” rating and a $250.00 target price on the stock. Evercore reaffirmed an “outperform” rating and issued a $230.00 price objective on shares of Danaher in a research report on Monday, July 6th. TD Cowen reduced their target price on Danaher from $240.00 to $236.00 and set a “buy” rating for the company in a report on Wednesday, July 22nd. Royal Bank Of Canada boosted their price target on Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research note on Monday. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $240.00 price target on shares of Danaher in a report on Wednesday, July 22nd. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $234.09.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.